CD117
| Aliases: | C-Kit, CD117, MASTC, PBT, SCFR |
|---|---|
| Other: | mast/stem cell growth factor receptor Kit|c-Kit protooncogene|p145 c-kit|piebald trait protein|proto-oncogene c-Kit|proto-oncogene tyrosine-protein kinase Kit|soluble KIT variant 1|tyrosine-protein kinase Kit|v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog|v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene-like protein |
This gene encodes a receptor tyrosine kinase. This gene was initially identified as a homolog of the feline sarcoma viral oncogene v-kit and is often referred to as proto-oncogene c-Kit. The canonical form of this glycosylated transmembrane protein has an N-terminal extracellular region with five immunoglobulin-like domains, a transmembrane region, and an intracellular tyrosine kinase domain at... see more
Vio Bright 515
| Common Laser: | 488 |
|---|---|
| Common Filter: | 525/50 |
| Excitation Peak: | 488 |
| Emission Peak: | 514 |
Vio®Bright® B515 from Miltenyi has an excitation peak at 488 nm and an emission peak at 514. It is comparable to BB515 in flow cytometry.
Popular CD117 Vio Bright 515 Antibodies
| Company / SKU |
Applications | Marker / Reactivity |
Host / Isotype / Clone |
Size / Price |
Details | |
|---|---|---|---|---|---|---|
|
Miltenyi Biotec 130-111-674 |
FC,MICS (MACSima Imaging Cyclic Staining),IF,IHC | CD117 Human |
Human IgG1 REA787 |
30 tests in 60 µL $195 |
Details | |
|
Miltenyi Biotec 130-116-733 |
FC | CD117 Human |
Human IgG1 REA996 |
30 tests in 60 µL $190 |
Details | |
|
Miltenyi Biotec 130-111-596 |
FC,MICS (MACSima Imaging Cyclic Staining),IF,IHC | CD117 Human |
Human IgG1 REA787 |
100 tests in 200 µL $480 |
Details | |
|
Miltenyi Biotec 130-116-612 |
FC | CD117 Human |
Human IgG1 REA996 |
100 tests in 200 µL $470 |
Details | |
|
Miltenyi Biotec 130-111-618 |
FC | CD117 Mouse |
Human IgG1 REA791 |
150 µg in 1 mL $625 |
Details | |
|
Miltenyi Biotec 130-111-696 |
FC | CD117 Mouse |
Human IgG1 REA791 |
30 µg in 200 µL $200 |
Details | |
| Browse CD117 / Vio Bright 515 antibodies. | ||||||


